| Product Name | MFGE8 Monoclonal Antibody |
|---|---|
| Description | Mouse monoclonal antibody to MFGE8 |
| Synonyms | Lactadherin,Breast epithelial antigen,BA46 ,HMFG,MFGM Milk fat globule-EGF factor 8 |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | 2B2D10 |
| Conjugate | Unconjugated |
| Immunogen | Recombinant Human MFGE8 protein |
| Isotype | IgG2b |
| Target | MFGE8 |
| Specificity | specific for MFGE8 native and denatured forms |
| Reactivity | Human |
| Applications | ELISA, IHC |
| Form | liquid |
| Diluent Buffer | Preservative: 0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 |
| Uniprot | Q08431 |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
| Background | Human MFGE8(milk fat globule-EGF factor 8;also lactadherin, breast epithelial antigen BA46, and medin) is a 46 kDa, secreted, monomeric glycoprotein that is associated with the human milk fat globule (HMFG) membrane.It is expressed by mammary epithelial cell surfaces, artery media, and in several carcinomas .Human MGFE8 is synthesized as a 387 amino acid (aa) precursor that contains a 23 aa signal sequence and a 364 aa mature region. The mature molecule contains four Nlinked glycosylation sites, an aminoterminal EGF like domain, plus C1 and C2 Iglike domains which are related to discoidin I and homologous to those of human coagulation factors V and VIII . Within the EGF like domain is an ArgGlyAsp(RGD) sequence, which is strategically placed in a hairpin loop between two antiparallel beta strands. In this way, the EGFlike domain serves as a scaffold for the RGD sequence, which is proposed to promote cell adhesion by binding cellsurface integrin receptors, such as ??v??3. Human MFGE8 shares 59%, 58%, 56%, and 52% aa sequence identity with porcine, bovine, rat, and mouse MFGE8,respectively. Functionally, MFGE8 in milk is reported to block rotavirus infection . MFGE8 expression by macrophages promotes the phagocytosis of apoptotic thymocytes by forming a bridge between phosphatidylserine on apoptotic cells, and ??v??3 integrin on phagocytes . The MFGE8 expression by macrophages controls the accumulation of apoptotic membrane fragments in atherosclerotic plaques and substantially limits lesion development . |
| Supplier | Cusabio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
